European Journal of Cardiovascular Medicine

Introduction: Cardiovascular diseases (CVDs) include coronary heart disease, cerebrovascular disorders, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, and pulmonary embolism among other conditions affecting the heart and blood vessels. The primary objective of this study was to examine the correlation between anxiety and depression and the risk of experiencing cardiovascular events and mortality after a myocardial infarction. Methods: The Cochrane review and preferred reporting item for systemic review (PRISMA) guidelines served as the basis for this systematic review. The systematic search was conducted from different database like Embase, Scopus, Medline, PubMed, PsycINFO, Google Scholar and Copernicus from inception to May 2023. Data on the number of patients, the country they were from, the age of diagnosis, anxiety, depression, cardiovascular events, myocardial infarction and death was collected. Result: 448 references were taken out because there were fewer of them. After the first round of evaluation, 286 out of the 323 citations were found to be unnecessary. The full texts of 37 publications were looked at to see if they could be included. Ten of them met the minimum requirements. This systematic review analysis on anxiety and depression with risk of subsequent cardiovascular events and death after myocardial infarction included a total of 3560 patients from 10 studies. Conclusion: A significant part of deaths and disabilities globally are caused by cardiovascular diseases, and the number of deaths related to these conditions has increased in India along with the country's population growth. Anxiety was discovered to be a distinct risk factor for the occurrence of CVD and cardiac death in those who were initially in good health. Future studies on the biobehavioral mechanisms relating the physiological and psychological conditions that exist prior to myocardial infraction and long-term mortality could improve risk classification, long-term surveillance, and the creation of specialized therapies for myocardial infraction patients.